• The Brigham is the first birth hospital in the nation to develop a program that offers parents an option to have their newborn screened for Duchenne • Through early diagnosis, screening may help ...
Genetic testing is available for adults as well as in vitro embryos, fetuses, newborns, and older children. Adults Adults planning to have children are advised to get genetic testing for muscular ...
Researchers at Cardiff University and Cardiff and Vale University Health Board have developed a more reliable method of screening for Duchenne muscular dystrophy (DMD) in newborn babies. In ...
The FDA gives marketing approval for a test that screens for Duchenne muscular dystrophy in newborns; acetaminophen is facing a possible statewide ban in California; the Supreme Court will not rush ...
A new genetic test targeting the most common types of muscular dystrophy -- those caused by mutations in the dystrophin gene -- is far quicker with greater accuracy and sensitivity than existing tests ...
Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...
The FDA Dec. 12 approved the marketing of a device used to detect Duchenne Muscular Dystrophy in newborns. The device, made by PerkinElmer, a Waltham, Mass.-based company that specializes in detecting ...
New treatments and gene-based therapies are changing the outlook for those living with Duchenne Muscular Dystrophy, a rare ...
RALEIGH, N.C., Aug. 6, 2021 /PRNewswire/ -- On Aug 06, both CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy, and Brigham and Women's ...
Early detection is critical for combating Duchenne muscular dystrophy. In today's Academic Minute, part of University at Albany Week, Bijan Dey looks into better testing methods. Dey is a principal ...
Prenatal diagnosis for Duchenne muscular dystrophy (DMD) was introduced in the Netherlands in 1984. We have investigated the impact of 26 years (1984–2009) of prenatal testing. Of the 635 prenatal ...
Entrada Therapeutics' drug for children with Duchenne muscular dystrophy fell well short of analyst expectations in an early-to-mid stage trial, sending its shares down more than 50% in premarket ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results